Cited by 178Viral Infectious Diseases and Gene Expression in InsectsMonoclonal and Polyclonal Antibodies ResearchProtein purification and stability

Guidelines to cell engineering for monoclonal antibody production

Open access
Rita Costa, A., Elisa Rodrigues, M., Henriques, Mariana, Azeredo, Joana, Oliveira, Rosário·2010·European Journal of Pharmaceutics and Biopharmaceutics

Abstract

Monoclonal antibodies (mAbs) are currently used for many diagnostic and therapeutic applications. The high demand for these biopharmaceuticals has led to the development of large-scale manufacturing processes, with productivity improvements being mainly achieved by optimization of bioreactor systems. However, more recently, the early steps of production, previous to bioreactor culture, have been presented as alternative areas where productivity enhancements can be achieved. Thus, this review describes the progress made for the improvement of productivity in mammalian expression systems for the high production of mAbs. Advances in the development of mAb-producing cell lines are being made, particularly regarding expression vector design and methods used for transfection, with the intent to create a reproducible methodology. Selection of the most suitable clones is also a critical step that can be improved, by including variables other than the expression level, which is still the common practice. Furthermore, strategies of cell engineering, although still mostly based on trial-and-error experimentation and not in standard protocols, hold great interest to improve cell growth and productivity, as well as product quality in the future. Improvements of the initial steps of the production process would not only result in cells with higher expression ability, but would also speed-up the process development.

Integrity signals

Registry

Crossref · 10.1016/j.ejpb.2009.10.002

Cites

218 of 218 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Transient expression is ideal for high throughput screening for hits identification and very helpful for early stage product characterization.

    “Yet, it is ideal for high throughput screening for hits identification and very helpful for early stage product characterization (Ozturk and Hu, 2005;Rosser et al., 2005;Rita Costa et al., 2010).”

    From Therapeutic glycoprotein production in mammalian cells (2017) · cites this paper as Rita Costa et al., 2010

  • By skipping the lengthy selection process for cells that have integrated the plasmid within their genome, transient transfection is much faster.

    “By skipping the lengthy selection process for the cells that have integrated the plasmid within their genome, transient transfection is much faster (Rita Costa et al., 2010).”

    From Therapeutic glycoprotein production in mammalian cells (2017) · cites this paper as Rita Costa et al., 2010

  • For stable expression, a gene marker is usually integrated in the expression plasmid along with the cDNA encoding the gene of interest, conferring a selective advantage to cells that integrate the plasmid into their genome.

    “For stable expression, a gene marker is usually integrated in the expression plasmid along with the cDNA encoding the gene of interest, conferring a selective advantage to the cells that integrate the plasmid into their genome (Rita Costa et al., 2010).”

    From Therapeutic glycoprotein production in mammalian cells (2017) · cites this paper as Rita Costa et al., 2010

Cites

Flagged first, then by citations

2 of the 220 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Authors
Rita Costa, A., Elisa Rodrigues, M., Henriques, M., Azeredo, J., & Oliveira, R.
Affiliations
Institute for Biotechnology and Bioengineering (PT)
Corresponding author
Henriques, Mariana
Venue
European Journal of Pharmaceutics and Biopharmaceutics
Publisher
Elsevier BV
Published
2010-02
Volume
74
Issue
2
Pages
127-138
ISSN
0939-6411 (ISSN-L)
OpenAlex
W2108422551
Cited by
178
References
220
Citations by year
2026: 2 · 2025: 8 · 2024: 10 · 2023: 12 · 2022: 8 · 2021: 14 · 2020: 11 · 2019: 9 · 2018: 13 · 2017: 17 · 2016: 8 · 2015: 10 · 2014: 15 · 2013: 20 · 2012: 10
FWCI
2.80
Type
journal article
Language
en
Open access
Locations
  • European Journal of Pharmaceutics and Biopharmaceutics (publishedVersion)
  • PubMed (publishedVersion)
  • RepositóriUM (Universidade do Minho) (submittedVersion, other-oa)
  • Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) (submittedVersion, cc-by-nc-nd)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Viral Infectious Diseases and Gene Expression in Insects
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Monoclonal and Polyclonal Antibodies Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein purification and stability
Keywords
monoclonal antibodies, cell engineering, mammalian cell expression systems, expression vector design, transfection, clone selection, antibody productivity, biopharmaceutical manufacturing, cell growth
MeSH terms
Animals, Antibodies, Monoclonal, Biotechnology, Humans, Technology, Pharmaceutical, Transfection, Protein Engineering, Cell Culture Techniques

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review